This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Anaplastic lymphoma kinase
From Proteopedia
(New page: Crystal Structure of human anaplastic lymphoma kinase complex with anti-cancer drug, 2xp2 {{STRUCTURE_2xp2| PDB=2xp2 | SIZE=350| SCENE= |right|C...) |
|||
| Line 35: | Line 35: | ||
[[2xp2]] – hALK + anti-cancer drug<br /> | [[2xp2]] – hALK + anti-cancer drug<br /> | ||
[[2yfx]], [[4anq]], [[4ans]] – hALK (mutant) + anti-cancer drug<br /> | [[2yfx]], [[4anq]], [[4ans]] – hALK (mutant) + anti-cancer drug<br /> | ||
| + | [[Category:Topic Page]] | ||
Revision as of 11:24, 28 April 2013
Anaplastic lymphoma kinase (ALK) which is a tyrosine kinase receptor is active in the development of the brain. Chromosomal translocation is observed in ca. 60% anaplastic large-cell lymphomas. The translocation creates a fusion gene composed of the 3’ end of ALK and the 5’ end of nucleophosmin gene. EML4/ALK fusion gene is observed in ca. 4% of non-small-cell lung cancer. Aberrant ALK activity is observed in other carcinomas as well. ALK is comprised by an extracellular domain, a single pass transmembrane domain and an intracellular kinase domain.
3D Structures of anaplastic lymphoma kinase
Updated on 28-April-2013
ALK kinase domain
2xb7, 2xba, 3aox – hALK + inhibitor – human
3l9p, 2yhv, 2yjr, 2yjs, 4fnw, 4fnx, 4anl – hALK (mutant)
3lcs – hALK (mutant) + staurosporine
4dce, 4fob, 4foc, 4fod, 4fny, 4fnz – hALK (mutant) + inhibitor
3lct – hALK (mutant) + ADP
2xp2 – hALK + anti-cancer drug
2yfx, 4anq, 4ans – hALK (mutant) + anti-cancer drug
